Home » LIGAND ANNOUNCES RECENTLY FILED SHAREHOLDER DERIVATIVE LAWSUIT
LIGAND ANNOUNCES RECENTLY FILED SHAREHOLDER DERIVATIVE LAWSUIT
Ligand Pharmaceuticals Incorporated today announced that the company, each member
of the Board of Directors and certain officers previously named in ongoing shareholder
litigation have been named as defendants in a shareholder derivative lawsuit
alleging breach of fiduciary duty and requesting disgorgement under the Sarbanes-Oxley
Act of 2002. Ligand believes that the allegations in the lawsuit, like those
in the existing derivative and class action lawsuits, are without merit and
intends to vigorously defend against them.
Genetic
Engineering News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May